Nasdaq · CIK 0001422143
KURA Kura Oncology, Inc.
Insider trading from SEC Form 4. Last filing 13 d ago. Close $10.60 on Oct 9, 2026, +43% from the 52-week low and -22% from the high.
Last 90 days
Net insider value
-$1.3M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
6
$1.3M by 6 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
KURAOct 9, 2026 · close 10.60
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Kura Oncology, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 19Weak | Teresa Brophy Bair Chief Legal Officer sell | $89k 8,442 shares | -4% | - | |
| 37Weak | Thomas James Doyle SVP, Finance & Accounting sell | $48k 4,607 shares | -3% | - | |
| 25Weak | Kathleen Ford Chief Operating Officer sell | $112k 10,574 shares | -7% | - | |
| 30Weak | Brian T. Powl Chief Commercial Officer sell | $345k 32,450 shares | -19% | - | |
| 32Weak | Mollie Leoni Chief Medical Officer sell | $440k 41,250 shares | -23% | - | |
| 37Weak | Francis Burrows Chief Scientific Officer sell | $225k 20,726 shares | -33% | - | |
| 40Moderate | Teresa Brophy Bair Chief Legal Officer sell | $95k 11,208 shares | -5% | +53% from low-30% from high | |
| 30Weak | Francis Burrows Chief Scientific Officer sell | $11k 1,311 shares | -4% | +53% from low-30% from high | |
| 37Weak | Thomas James Doyle SVP, Finance & Accounting sell | $60k 7,142 shares | -5% | +53% from low-30% from high | |
| 35Weak | Kathleen Ford Chief Operating Officer sell | $15k 1,813 shares | -1% | +53% from low-30% from high | |
| 38Weak | Mollie Leoni Chief Medical Officer sell | $69k 8,180 shares | -3% | +53% from low-30% from high | |
| 37Weak | Brian T. Powl Chief Commercial Officer sell | $54k 6,414 shares | -3% | +53% from low-30% from high | |
| 31Weak | Francis Burrows Chief Scientific Officer sell | $232k 23,726 shares | -41% | +78% from low-19% from high | |
| 8Weak | Faheem Hasnain director sell | $110k 10,000 shares | -29% | +93% from low-12% from high | |
| 20Weak | Teresa Brophy Bair Chief Legal Officer sell | $98k 8,804 shares | -4% | +102% from low-32% from high | |
| 37Weak | Thomas James Doyle SVP, Finance & Accounting sell | $51k 4,539 shares | -3% | +102% from low-32% from high | |
| 23Weak | Kathleen Ford Chief Operating Officer sell | $77k 6,902 shares | -6% | +102% from low-32% from high | |
| 41Moderate | Mollie Leoni Chief Medical Officer sell | $173k 15,485 shares | -6% | +102% from low-32% from high | |
| 40Moderate | Brian T. Powl Chief Commercial Officer sell | $99k 8,887 shares | -6% | +102% from low-32% from high | |
| 19Weak | Teresa Brophy Bair Chief Legal Officer sell | $79k 8,805 shares | -6% | +62% from low-54% from high | |
| 36Weak | Thomas James Doyle SVP, Finance & Accounting sell | $41k 4,541 shares | -4% | +62% from low-54% from high | |
| 22Weak | Kathleen Ford Chief Operating Officer sell | $62k 6,892 shares | -10% | +62% from low-54% from high | |
| 60Notable | Troy Edward Wilson President and CEO sell | $327k 36,615 shares | -13% | +62% from low-54% from high | |
| 40Moderate | Mollie Leoni Chief Medical Officer sell | $110k 12,314 shares | -7% | +62% from low-54% from high | |
| 39Weak | Brian T. Powl Chief Commercial Officer sell | $80k 8,891 shares | -8% | +62% from low-54% from high | |
| 64Notable | Troy Edward Wilson President & CEO buy | $410k 50,000 shares | +98% | +47% from low-61% from high | |
| 57Moderate | Troy Edward Wilson President and CEO buy | $303k 50,000 shares | +5165% | +12% from low-71% from high | |
| 3Weak | Teresa Brophy Bair Chief Legal Officer sell | $9,292 1,559 shares | -1% | +11% from low-70% from high | |
| 8Weak | Kathleen Ford Chief Operating Officer sell | $9,777 1,558 shares | -7% | +11% from low-70% from high | |
| 2Weak | Faheem Hasnain director sell | $181k 22,682 shares | -49% | - | |
| 37Weak | Teresa Brophy Bair Chief Legal Officer sell | $57k 7,281 shares | -6% | - | |
| 30Weak | Francis Burrows Chief Scientific Officer sell | $17k 2,166 shares | -9% | - | |
| 36Weak | Thomas James Doyle SVP, Finance & Accounting sell | $39k 4,949 shares | -5% | - | |
| 35Weak | Kathleen Ford Chief Operating Officer sell | $14k 1,817 shares | -8% | - | |
| 30Weak | Brian T. Powl Chief Commercial Officer sell | $12k 1,583 shares | -3% | - | |
| 36Weak | Mollie Leoni Chief Medical Officer sell | $39k 4,963 shares | -5% | - | |
| 0Weak | Kathleen Ford Chief Operating Officer sell | $8,434 526 shares | -2% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | Thomas James Doyle SVP, Finance & Accounting | SOpen-market sale Common Stock | -4,607 | $10.50 | $48k | 142,428 | 13 d ago |
| Sep 28, 2026 | Mollie Leoni Chief Medical Officer | SOpen-market sale Common Stock | -12,448 | $10.50 | $131k | 169,897 | 13 d ago |
| Sep 28, 2026 | Kathleen Ford Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -6,906 | $10.50 | $72k | 146,654 | 13 d ago |
| Sep 28, 2026 | Teresa Brophy Bair Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -8,442 | $10.50 | $89k | 187,002 | 13 d ago |
| Sep 28, 2026 | Brian T. Powl Chief Commercial Officer | SOpen-market sale Common Stock | -9,020 | $10.50 | $95k | 160,249 | 13 d ago |
| Sep 29, 2026 | Mollie Leoni Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -28,802 | $10.75 | $310k | 141,095 | 13 d ago |
| Sep 29, 2026 | Kathleen Ford Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -3,668 | $10.75 | $39k | 142,986 | 13 d ago |
| Sep 28, 2026 | Brian T. Powl Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -8,000 | $10.56 | $84k | 152,249 | 13 d ago |
| Sep 29, 2026 | Brian T. Powl Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -15,430 | $10.75 | $166k | 136,819 | 13 d ago |
| Sep 24, 2026 | Francis Burrows Chief Scientific Officer | MOption exercise Common Stock | +30,000 | $6.15 | $185k | 63,053 | 17 d ago |
| Sep 24, 2026 | Francis Burrows Chief Scientific Officer | SOpen-market sale Common Stock | -20,726 | $10.83 | $225k | 42,327 | 17 d ago |
| Sep 24, 2026 | Francis Burrows Chief Scientific Officer | MOption exercise Stock Option (Right to Buy)derivative | -30,000 | $0.00 | $0 | 0 | 17 d ago |
| Sep 8, 2026 | Jennifer Fulk Chief Financial Officer | AGrant or award Option to purchase common stockderivative10b5-1 | +450,000 | $0.00 | $0 | 450,000 | 32 d ago |
| Mar 23, 2026 | Troy Edward Wilson President and CEO | MOption exercise Common Stock | +6,103 | $6.15 | $38k | 435,456 | Mar 25, 2026 |
| Mar 23, 2026 | Troy Edward Wilson President and CEO | MOption exercise Stock Option (Right to Buy)derivative | +6,103 | $0.00 | $0 | 0 | Mar 25, 2026 |
| Mar 18, 2026 | Thomas Malley director | MOption exercise Common Stock | +10,000 | $3.12 | $31k | 10,000 | Mar 20, 2026 |
| Mar 18, 2026 | Thomas Malley director | MOption exercise Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 0 | Mar 20, 2026 |
| Jan 27, 2026 | Brian T. Powl Chief Commercial Officer | SOpen-market sale Common Stock | -4,842 | $8.46 | $41k | 184,847 | Jan 27, 2026 |
| Jan 27, 2026 | Francis Burrows Chief Scientific Officer | SOpen-market sale Common Stock | -1,311 | $8.46 | $11k | 32,424 | Jan 27, 2026 |
| Jan 27, 2026 | Thomas James Doyle SVP, Finance & Accounting | SOpen-market sale Common Stock | -2,226 | $8.46 | $19k | 150,083 | Jan 27, 2026 |
| Jan 27, 2026 | Teresa Brophy Bair Chief Legal Officer | SOpen-market sale Common Stock | -4,096 | $8.46 | $35k | 234,043 | Jan 27, 2026 |
| Jan 27, 2026 | Kathleen Ford Chief Operating Officer | SOpen-market sale Common Stock | -1,813 | $8.46 | $15k | 153,560 | Jan 27, 2026 |
| Jan 27, 2026 | Mollie Leoni Chief Medical Officer | SOpen-market sale Common Stock | -3,655 | $8.46 | $31k | 271,799 | Jan 27, 2026 |
| Jan 27, 2026 | Teresa Brophy Bair Chief Legal Officer | SOpen-market sale Common Stock | -2,335 | $8.46 | $20k | 231,708 | Jan 27, 2026 |
| Jan 27, 2026 | Brian T. Powl Chief Commercial Officer | SOpen-market sale Common Stock | -1,572 | $8.46 | $13k | 183,275 | Jan 27, 2026 |
| Jan 27, 2026 | Mollie Leoni Chief Medical Officer | SOpen-market sale Common Stock | -2,233 | $8.46 | $19k | 269,566 | Jan 27, 2026 |
| Jan 27, 2026 | Thomas James Doyle SVP, Finance & Accounting | SOpen-market sale Common Stock | -1,114 | $8.46 | $9,425 | 148,969 | Jan 27, 2026 |
| Jan 27, 2026 | Teresa Brophy Bair Chief Legal Officer | SOpen-market sale Common Stock | -4,777 | $8.46 | $40k | 226,931 | Jan 27, 2026 |
| Jan 27, 2026 | Thomas James Doyle SVP, Finance & Accounting | SOpen-market sale Common Stock | -695 | $8.46 | $5,880 | 148,274 | Jan 27, 2026 |
| Jan 27, 2026 | Mollie Leoni Chief Medical Officer | SOpen-market sale Common Stock | -951 | $8.46 | $8,046 | 268,615 | Jan 27, 2026 |
| Jan 27, 2026 | Thomas James Doyle SVP, Finance & Accounting | SOpen-market sale Common Stock | -2,226 | $8.46 | $19k | 146,048 | Jan 27, 2026 |
| Jan 27, 2026 | Mollie Leoni Chief Medical Officer | SOpen-market sale Common Stock | -1,341 | $8.46 | $11k | 267,274 | Jan 27, 2026 |
| Jan 27, 2026 | Thomas James Doyle SVP, Finance & Accounting | SOpen-market sale Common Stock | -881 | $8.46 | $7,454 | 145,167 | Jan 27, 2026 |
| Jan 2, 2026 | Francis Burrows Chief Scientific Officer | AGrant or award Option to purchase common stockderivative | +185,000 | $0.00 | $0 | 185,000 | Jan 6, 2026 |
| Jan 2, 2026 | Thomas James Doyle SVP, Finance & Accounting | AGrant or award Common Stock | +21,250 | $0.00 | $0 | 152,309 | Jan 6, 2026 |
| Jan 2, 2026 | Teresa Brophy Bair Chief Legal Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 238,139 | Jan 6, 2026 |
| Jan 2, 2026 | Kathleen Ford Chief Operating Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 155,373 | Jan 6, 2026 |
| Jan 2, 2026 | Brian T. Powl Chief Commercial Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 189,689 | Jan 6, 2026 |
| Jan 2, 2026 | Mollie Leoni Chief Medical Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 275,454 | Jan 6, 2026 |
| Jan 2, 2026 | Troy Edward Wilson President and CEO | AGrant or award Option to purchase common stockderivative | +1,120,000 | $0.00 | $0 | 1,120,000 | Jan 6, 2026 |
| Jan 2, 2026 | Teresa Brophy Bair Chief Legal Officer | AGrant or award Option to purchase common stockderivative | +100,000 | $0.00 | $0 | 100,000 | Jan 6, 2026 |
| Jan 2, 2026 | Kathleen Ford Chief Operating Officer | AGrant or award Option to purchase common stockderivative | +100,000 | $0.00 | $0 | 100,000 | Jan 6, 2026 |
| Jan 2, 2026 | Brian T. Powl Chief Commercial Officer | AGrant or award Option to purchase common stockderivative | +100,000 | $0.00 | $0 | 100,000 | Jan 6, 2026 |
| Jan 2, 2026 | Mollie Leoni Chief Medical Officer | AGrant or award Option to purchase common stockderivative | +100,000 | $0.00 | $0 | 100,000 | Jan 6, 2026 |
| Jan 2, 2026 | Thomas James Doyle SVP, Finance & Accounting | AGrant or award Option to purchase common stockderivative | +42,500 | $0.00 | $0 | 42,500 | Jan 6, 2026 |
| Dec 18, 2025 | Francis Burrows Chief Scientific Officer | MOption exercise Common Stock | +35,000 | $4.80 | $168k | 57,461 | Dec 19, 2025 |
| Dec 18, 2025 | Francis Burrows Chief Scientific Officer | SOpen-market sale Common Stock | -23,726 | $9.78 | $232k | 33,735 | Dec 19, 2025 |
| Dec 18, 2025 | Francis Burrows Chief Scientific Officer | MOption exercise Stock Option (Right to Buy)derivative | -35,000 | $0.00 | $0 | 0 | Dec 19, 2025 |
| Dec 9, 2025 | Faheem Hasnain director | MOption exercise Common Stock10b5-1 | +10,000 | $3.12 | $31k | 33,983 | Dec 10, 2025 |
| Dec 9, 2025 | Faheem Hasnain director | SOpen-market sale Common Stock10b5-1 | -10,000 | $10.98 | $110k | 23,983 | Dec 10, 2025 |
| Nov 13, 2025 | Teresa Brophy Bair Chief Legal Officer | AGrant or award Common Stock10b5-1 | +48,900 | $0.00 | $0 | 196,943 | Nov 14, 2025 |
| Nov 13, 2025 | Thomas James Doyle SVP, Finance & Accounting | AGrant or award Common Stock | +24,967 | $0.00 | $0 | 134,796 | Nov 14, 2025 |
| Nov 13, 2025 | Kathleen Ford Chief Operating Officer | AGrant or award Common Stock10b5-1 | +48,900 | $0.00 | $0 | 112,275 | Nov 14, 2025 |
| Nov 13, 2025 | Mollie Leoni Chief Medical Officer | AGrant or award Common Stock | +82,500 | $0.00 | $0 | 240,939 | Nov 14, 2025 |
| Nov 13, 2025 | Brian T. Powl Chief Commercial Officer | AGrant or award Common Stock | +48,900 | $0.00 | $0 | 148,576 | Nov 14, 2025 |
| Nov 13, 2025 | Troy Edward Wilson President and CEO | AGrant or award Common Stock | +182,500 | $0.00 | $0 | 429,353 | Nov 14, 2025 |
| Nov 14, 2025 | Teresa Brophy Bair Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -8,804 | $11.18 | $98k | 188,139 | Nov 14, 2025 |
| Nov 14, 2025 | Thomas James Doyle SVP, Finance & Accounting | SOpen-market sale Common Stock | -4,539 | $11.18 | $51k | 130,257 | Nov 14, 2025 |
| Nov 14, 2025 | Kathleen Ford Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -6,902 | $11.18 | $77k | 105,373 | Nov 14, 2025 |
| Nov 14, 2025 | Mollie Leoni Chief Medical Officer | SOpen-market sale Common Stock | -15,485 | $11.18 | $173k | 225,454 | Nov 14, 2025 |
| Nov 14, 2025 | Brian T. Powl Chief Commercial Officer | SOpen-market sale Common Stock | -8,887 | $11.18 | $99k | 139,689 | Nov 14, 2025 |
| Sep 27, 2025 | Teresa Brophy Bair Chief Legal Officer | AGrant or award Common Stock10b5-1 | +48,900 | $0.00 | $0 | 156,848 | Sep 29, 2025 |
| Sep 27, 2025 | Thomas James Doyle SVP, Finance & Accounting | AGrant or award Common Stock | +24,966 | $0.00 | $0 | 114,370 | Sep 29, 2025 |
| Sep 27, 2025 | Kathleen Ford Chief Operating Officer | AGrant or award Common Stock10b5-1 | -48,900 | $0.00 | $0 | 70,267 | Sep 29, 2025 |
| Sep 27, 2025 | Troy Edward Wilson President and CEO | AGrant or award Common Stock | +182,500 | $0.00 | $0 | 283,468 | Sep 29, 2025 |
| Sep 27, 2025 | Mollie Leoni Chief Medical Officer | AGrant or award Common Stock | +82,500 | $0.00 | $0 | 170,753 | Sep 29, 2025 |
| Sep 27, 2025 | Brian T. Powl Chief Commercial Officer | AGrant or award Common Stock | +48,900 | $0.00 | $0 | 108,567 | Sep 29, 2025 |
| Sep 29, 2025 | Kathleen Ford Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -6,892 | $8.94 | $62k | 63,375 | Sep 29, 2025 |
| Sep 29, 2025 | Troy Edward Wilson President and CEO | SOpen-market sale Common Stock | -36,615 | $8.94 | $327k | 246,853 | Sep 29, 2025 |
| Sep 29, 2025 | Mollie Leoni Chief Medical Officer | SOpen-market sale Common Stock | -12,314 | $8.94 | $110k | 158,439 | Sep 29, 2025 |
| Sep 29, 2025 | Brian T. Powl Chief Commercial Officer | SOpen-market sale Common Stock | -8,891 | $8.94 | $80k | 99,676 | Sep 29, 2025 |
| Sep 29, 2025 | Teresa Brophy Bair Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -8,805 | $8.94 | $79k | 148,043 | Sep 29, 2025 |
| Sep 29, 2025 | Thomas James Doyle SVP, Finance & Accounting | SOpen-market sale Common Stock | -4,541 | $8.94 | $41k | 109,829 | Sep 29, 2025 |
| Sep 8, 2025 | Troy Edward Wilson President & CEO | POpen-market purchase Common Stock | +50,000 | $8.20 | $410k | 100,968 | Sep 9, 2025 |
| Aug 12, 2025 | Troy Edward Wilson President and CEO | POpen-market purchase Common Stock | +36,506 | $5.85 | $214k | 37,474 | Aug 14, 2025 |
| Aug 13, 2025 | Troy Edward Wilson President and CEO | POpen-market purchase Common Stock | +13,494 | $6.64 | $90k | 50,968 | Aug 14, 2025 |
| Jun 5, 2025 | Helen Louise Collins director | AGrant or award Option to purchase common stockderivative | +28,500 | $0.00 | $0 | 28,500 | Jun 6, 2025 |
| Jun 5, 2025 | Faheem Hasnain director | AGrant or award Option to purchase common stockderivative | +28,500 | $0.00 | $0 | 28,500 | Jun 6, 2025 |
| Jun 5, 2025 | Mary T Szela director | AGrant or award Option to purchase common stockderivative | +28,500 | $0.00 | $0 | 28,500 | Jun 6, 2025 |
| Jun 5, 2025 | Thomas Malley director | AGrant or award Option to purchase common stockderivative | +28,500 | $0.00 | $0 | 28,500 | Jun 6, 2025 |
| Jun 5, 2025 | Michael Vasconcelles director | AGrant or award Option to purchase common stockderivative | +28,500 | $0.00 | $0 | 28,500 | Jun 6, 2025 |
| Jun 5, 2025 | Carol Schafer director | AGrant or award Option to purchase common stockderivative | +28,500 | $0.00 | $0 | 28,500 | Jun 6, 2025 |
| Jun 5, 2025 | Diane L. Parks director | AGrant or award Option to purchase common stockderivative | +28,500 | $0.00 | $0 | 28,500 | Jun 6, 2025 |
| May 19, 2025 | Teresa Brophy Bair Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -1,559 | $5.96 | $9,292 | 107,948 | May 19, 2025 |
| May 19, 2025 | Kathleen Ford Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -1,558 | $6.28 | $9,777 | 21,367 | May 19, 2025 |
| Mar 21, 2025 | Faheem Hasnain director | MOption exercise Common Stock10b5-1 | +22,682 | $6.32 | $143k | 46,665 | Mar 24, 2025 |
| Mar 21, 2025 | Faheem Hasnain director | SOpen-market sale Common Stock10b5-1 | -22,682 | $8.00 | $181k | 23,983 | Mar 24, 2025 |
| Jan 28, 2025 | Teresa Brophy Bair Chief Legal Officer | SOpen-market sale Common Stock | -2,437 | $7.87 | $19k | 112,792 | Jan 28, 2025 |
| Jan 28, 2025 | Francis Burrows Chief Scientific Officer | SOpen-market sale Common Stock | -846 | $7.87 | $6,660 | 22,025 | Jan 28, 2025 |
| Jan 28, 2025 | Thomas James Doyle SVP, Finance & Accounting | SOpen-market sale Common Stock | -2,241 | $7.87 | $18k | 90,901 | Jan 28, 2025 |
| Jan 28, 2025 | Kathleen Ford Chief Operating Officer | SOpen-market sale Common Stock | -1,817 | $7.87 | $14k | 21,367 | Jan 28, 2025 |
| Jan 28, 2025 | Brian T. Powl Chief Commercial Officer | SOpen-market sale Common Stock | -1,583 | $7.87 | $12k | 59,667 | Jan 28, 2025 |
| Jan 28, 2025 | Mollie Leoni Chief Medical Officer | SOpen-market sale Common Stock | -2,253 | $7.87 | $18k | 90,963 | Jan 28, 2025 |
| Jan 28, 2025 | Teresa Brophy Bair Chief Legal Officer | SOpen-market sale Common Stock | -4,844 | $7.87 | $38k | 107,948 | Jan 28, 2025 |
| Jan 28, 2025 | Francis Burrows Chief Scientific Officer | SOpen-market sale Common Stock | -1,320 | $7.87 | $10k | 20,705 | Jan 28, 2025 |
| Jan 28, 2025 | Thomas James Doyle SVP, Finance & Accounting | SOpen-market sale Common Stock | -887 | $7.87 | $6,982 | 90,014 | Jan 28, 2025 |
| Jan 28, 2025 | Mollie Leoni Chief Medical Officer | SOpen-market sale Common Stock | -1,353 | $7.87 | $11k | 89,610 | Jan 28, 2025 |
| Jan 28, 2025 | Thomas James Doyle SVP, Finance & Accounting | SOpen-market sale Common Stock | -699 | $7.87 | $5,502 | 89,315 | Jan 28, 2025 |
| Jan 28, 2025 | Mollie Leoni Chief Medical Officer | SOpen-market sale Common Stock | -816 | $7.87 | $6,423 | 88,794 | Jan 28, 2025 |
| Jan 28, 2025 | Thomas James Doyle SVP, Finance & Accounting | SOpen-market sale Common Stock | -1,122 | $7.87 | $8,832 | 88,193 | Jan 28, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Teresa Brophy BairChief Legal Officer
- Francis BurrowsChief Scientific Officer
- Helen Louise Collinsofficer, director
- Thomas James DoyleSVP, Finance & Accounting
- Kathleen FordChief Operating Officer
- Jennifer FulkChief Financial Officer
- Faheem Hasnainceo, president, officer, director
- Mollie LeoniChief Medical Officer
- Thomas Malleydirector
- Diane L. Parksdirector
- Brian T. PowlChief Commercial Officer
- Carol Schaferdirector
- Mary T Szelaceo, president, officer, director
- Michael Vasconcellesofficer, director
- Troy Edward WilsonPresident and CEO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.